Why the study?
Does early parenteral copper-histidine supplementation improve clinical outcomes in a patient with Menkes disease and residual ATP7A activity?
Does early parenteral copper-histidine supplementation improve clinical outcomes in a patient with Menkes disease and residual ATP7A activity?
Early-onset and long-term copper treatment can lead to prolonged survival and mild symptoms in Menkes disease patients with residual ATP7A activity.
Answers are grounded in this paper and cite their sources.
Suggests early copper-histidine supplementation may prolong survival in Menkes disease with residual ATP.
Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper-histidine supplementation may modify disease progression substantially but beneficial effects of long-term treatment have been recorded in only a few patients. Here we report on the eldest surviving MD patient (37 years) receiving early-onset and long-term copper treatment. He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. These findings suggest that some cuproenzymes maintain their function when sufficient copper is provided to the cells; and underline the importance of early initiated copper treatment, efficiency of which is likely to be dependent on the mutant ATP7A function.
No takes yet. Share an insight, caveat, or question.
Tümer et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: